Back to News
Market Impact: 0.3
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights
Source: PR Newswire
Legal & LitigationHealthcare & Biotech
DJS Law Group reminded investors of a securities class action lawsuit against ARS Pharmaceuticals (NASDAQ: SPRY), alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5. The litigation introduces potential financial, reputational and governance risks for the biotech company, although the excerpt provides no alleged damages, class period, or operational impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
SPRY-0.85
More News
- Looters hit 3,000 French businesses. Within hours, the haul was trending on Vinted under the riot’s date
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- J&J prostate cancer drug shows promising tumor responses in early trial
- Exclusive-Boeing supplier dispute has halted 777 freighter production for two months, sources say
- Meta shares are down 9% this week. Here's why Mike Khouw is buying now